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Background: The aim of this study was to examine the association of non-random X chromosome inactivation
(XCI) and loss of heterozygosity (LOH) at Xq25 with breast cancer development.
Methods: Seventy-nine breast cancer patients, 39 female lung cancer patients, 30 other cancer patients and 77
healthy females were analysed for LOH using a panel of 11 microsatellite markers spanning Xq25. The androgen
receptor (AR) gene was chosen as an XCI marker.
Results: LOH of at least one microsatellite locus at Xq25 was identified in 46/65 breast cancers examined, while
only 10/25 cancers of other origins demonstrated LOH in this region (p = 0.014). The critical deletion region in
breast cancer was around marker DXS1047 (47.23%). Moreover, we found that tissues from eight breast cancers
showed LOH at all of the informative loci tested at Xq25, while the other 38 showed partial (interstitial or telomeric)
alterations at Xq25. Interestingly, the pattern of XCI of these eight breast cancers tended to be non-random.
We estimated the frequencies of AR alleles and found that women with two long AR alleles (≥21 CAG repeats) had
an increased risk of developing breast cancer, while those with two short AR alleles (<21 CAG repeats) were likely
to be normal (p = 0.00069).
Conclusions: The extraordinary high frequencies of LOH at Xq25 found in this study strongly imply that there
might be one or more tumour suppressor genes (TSGs) related to the development of breast cancer at Xq25 in the
Taiwanese female population.
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Human female cells possess two X chromosomes, while
male cells have only one. To compensate for X chromo-
some gene dosage, one X chromosome in each female
cell condenses to form a Barr body. Genes on this
chromosome are thus shut down in a phenomenon
known as X chromosome inactivation (XCI). Which X
chromosome undergoes condensation is generally ran-
dom, therefore theoretically the ratio of paternal inacti-
vation vs. maternal should be 1:1 in a given mass of
cells. This phenomenon is known as Lyonization [1,2].* Correspondence: chien@cc.ncue.edu.tw
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reproduction in any medium, provided the orHowever, the pattern of XCI in some women is not ran-
dom (non-random, or skewed Lyonization). Some re-
search suggests that women with non-random XCI are
more likely to be affected by X-linked recessive diseases,
such as Wiskott-Aldrich syndrome [3], Hunter’s syndrome
[4], Haemophilia [5], Duchenne’s muscular dystrophy [6],
and Borjeson-Forssman-Lehmann syndrome [7]. Females
are carriers of X chromosome mutations and do not usu-
ally express the phenotype because the normal allele can
compensate for the defect, hence men are more likely to
be affected by X-linked recessive diseases. However, non-
random XCI in women can mimic the effects of the single
X chromosome in men if the mutated X chromosome is
active and the normal X chromosome is inactive, leading
to expression of X-linked recessive diseases in women.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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demonstrate the pattern of X chromosome inactivation
[8-10]. The 5′ CpG island of the AR gene is methylated
on the inactive X chromosome and hypomethylated on
the active X chromosome. Additionally, the AR alleles of
paternal and maternal origins may be distinguished by a
highly polymorphic CAG triplet repeat within the region
of the CpG island. Moreover, the methylation status of a
restriction site (GCGC) that is less than 100 bp away from
the polymorphic CAG triplet repeat can be recognized by
the methylation-sensitive restriction enzymes HpaII and
HhaI [11]. Amplification of the CpG island region by poly-
merase chain reaction (PCR) following methylation-
sensitive restriction enzyme digestion is possible only
when the AR gene is fully methylated. Therefore, compar-
ing the AR allele ratio with or without digestion of enzyme
is a convenient method to determine whether the pattern
of XCI is random or non-random.
The AR gene contains a polymorphic CAG trinucleo-
tide repeat that encodes an uninterrupted polyglutamine
tract in the N-terminal domain, ranging from 6–39 re-
peats in healthy individuals [12]. The number of CAG
repeats has been linked with hormone-related cancers in
both men and women. Several studies have demon-
strated that shorter CAG repeat length is associated with
increased prostate cancer risk [13]. Multiple studies have
also identified associations between CAG repeat length
and the risk of ovarian [14], breast [15,16] and endomet-
rial cancers [17,18]. In these studies, the allele patterns
were defined as the length of the CAG repeat region.
For instance, Terry et al. (2005) found that women with
of two long AR alleles (≥22 CAG repeats) had an in-
creased risk of ovarian cancer compared with those pos-
sessing two short AR alleles (<22 CAG repeats) [19].
However, the results varied with differences in popula-
tion and sample size [17,18].
Deletions on the X chromosome often occur in female
cancers. Deletions at Xq25 have been reported to be as-
sociated with ovarian cancer [20,21], and a high fre-
quency of loss of heterozygosity (LOH) has been found
on chromosome arm Xq. The study of LOH with a
series of polymorphic microsatellite markers at Xq25 in
breast cancer patients found that LOH of DXS8098 was
associated with larger tumour size (>3 cm), higher histo-
logical grade, and axillary lymph node metastasis. This
suggests that there could be one or more TSGs in this
region and that the DXS8098 locus on Xq25 could be
used as a prognostic marker for breast cancer.
According to Knudson’s two hit hypothesis, we hypothe-
sized that female breast cancer patients may have a high
incidence of LOH at Xq25 and that their tumour tissues
would exhibit non-random XCI. The occurrence of breast
cancer may result from inactivation of a TSG in this re-
gion. When a mutated X chromosome with LOH at Xq25is active while the normal X chromosome is inactive; can-
cer may eventuate. Then, we can examine whether there
might be a candidate tumour suppressor gene at Xq25.
Methods
Patients and samples
Seventy-nine breast cancer patients, 39 female lung cancer
patients, 30 female other cancer patients (including gastric
and liver cancer patients) from Changhua Christian
Hospital and 77 healthy females were analysed. The 77
healthy females were divided into an old healthy control
group (32–73 years, average 50.81 ± 11.32 years) and a
young healthy control group (20–29 years, average 22.86 ±
2.24 years). Tumour and adjacent normal tissues were
obtained after surgery and immediately stored in liquid
nitrogen or at −70°C for further DNA extraction. The
research was approved by Changhua Christian Hospital
Institutional Review Board and informed consent was
obtained from all patients.
Microsatellite analysis
A panel of 11 microsatellite markers spanning Xq25 was
used for LOH analysis (DXS8067, DXS1001, DXS8059,
DXS8098, DXS8009, DXS1047, DXS8068, DXS8078,
DXS8071, DXS8041, and DXS8074). These primer se-
quences were obtained from the NCBI (http://www.ncbi.
nlm.nih.gov/projects/genome/guide/human/.
DNA extracted from tumour tissues or adjacent nor-
mal tissues of cancer patients was amplified using these
microsatellite markers. PCR reactions were performed in
a GeneAmp PCR system 2700 thermal cycler (Applied
Biosystems, Foster City, CA, USA).
LOH analysis was performed using an ABI Prism 3100
Genetic Analyser. Each forward primer was fluorescein-
labelled, allowing amplified fragments to be quantified
using ABI PRlSM 3100 GeneScan 3.1 software (Applied
Biosystems), which calculated the sizes and areas of sig-
nal peaks. The allele ratio was determined as the peak
height of the smaller allele divided by that of the larger,
and QLOH was then determined by dividing the tumour
allele ratio by the normal allele ratio as per the formula
QLOH = (T1/T2) / (N1/N2), where T1 and N1 are the
smaller allele peak heights in the tumour DNA and in
the neighbouring normal DNA, respectively, and T2 and
N2 are the larger allele peak heights in the tumour DNA
and in the neighbouring normal DNA, respectively. As
previously reported, an arbitrary normal range of QLOH
was set from 0.75 to 1.33with a QLOH lower than 0.75 or
greater than 1.33 was defined as LOH [22].
XCI pattern analysis
The AR gene is located on the X chromosome and was
chosen as an XCI marker. DNA (200 ng) was digested
with 10 U HhaI (Fermentas) at 37°C for 12 hr and then
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DNA was cleaned by MultiScreen-PCR (96-Well Filtration
System, Millipore) and 20 μL ddH2O was added to dis-
solve the DNA. Control experiments were performed in
the same manner except that HhaI was not added during
the digestion period. The PCR reactions and fragment
analysis were carried out as previously described [11]. The
XCI pattern (random or non-random) was determined by
the modified allelic cleavage ratio (CR) of AR, as calcu-
lated by dividing the smaller peak area ratio by that of
the larger. While the Lyon hypothesis, predicts that a
normal CR should be 1.0, in reality the XCI pattern is
slightly skewed [23]. It is widely accepted that an arbi-
trary normal value of CR (random XCI pattern) ranges
from 0.33 to 3.00 [24]. Therefore, a CR lower than 0.33
or greater than 3.00 was defined as a non-random XCI
pattern.Statistical analysis
The χ2-test, Fisher’s exact test, and Yate’s correction for
continuity were used for statistical analysis of the results.
Two-tailed p values of <0.05 were considered statistically
significant.Results
Frequency of LOH in breast cancers
The panel of 11 microsatellite markers at Xq25 was used
to analyse QLOH in tumour DNA obtained from breast
and other cancer patients, and the results are as presented
in Table 1. The highest frequency of LOH was observed at
DXS1047, with 47.23% (26/55) of the breast cancer tissues
showing allelic loss, followed by DXS8067 (44.83%),Table 1 Frequency of heterozygosity and LOH in breast cance
Sample Breast Cancers (BC)













The frequency of heterozygosity and LOH in the breast cancers (BC) and other canc
a. informative: patients with heterozygosity.
b. LOH %: number of patients with LOH divided by number of patients with hetero
c. Chi-square test and Fisher’s exact probability test.DXS8068 (39.22%), DXS8059 (38.24%), DXS8074 (34.4%),
DXS8071 (30.8%), and DXS1001 (30.36%). The frequency
of LOH at other microsatellite markers was below
30%. The critical deletion region was around DXS1047
(47.23%).
At least one microsatellite locus at Xq25 showing
LOH was detected in the tumour DNA of 46 (70.7%) of
the 65 breast cancers. Eight of those 65 samples (B44,
B113, B130, B129, B307, B320, B322, and B323) showed
LOH at all the informative loci tested at Xq25, whereas
38 others showed partial (interstitial or telomeric) alter-
ations at Xq25. A schematic map of LOH at Xq25 in
these breast cancer patients is shown in Figure 1. LOH
at Xq25 was not identified using these markers in the
remaining 19 cases. These results indicate that a com-
monly deleted region at Xq25 exists in breast cancer pa-
tients and that the highest frequency of LOH occurred
at the DXS1047 loci.Frequency of LOH in the other cancers
The same 11 microsatellite markers at Xq25 were used
to detect LOH in the 25 patients with other cancers, in-
cluding lung and stomach cancers (Table 1). The highest
frequency of LOH was observed at DXS8009, with 37.5%
(6/16) of these tumour tissues showing allele loss. The
frequencies of LOH at DXS1001, DXS8068 and, DXS8067
were about 30%, while the ratio of LOH at other microsat-
ellite markers was quite low at below 20%. Furthermore,
no evidence of LOH at DXS8071 was detected in these tis-
sues. At least one Xq25 microsatellite locus showed LOH
in 40.0% (10/25) of these other cancer tissues, and in
70.7% (46/65) of the breast cancer tissues (p = 0.014).r and other cancer tissue
Other Cancers (OC) P
nformativea LOHb % LOH/informative LOH % valuec
13/29 44.83% 5/17 29.4% 0.47
17/56 30.36% 6/19 31.6% 0.85
13/34 38.24% 1/8 12.5% 0.17
13/46 28.24% 7/17 14.1% 0.50
14/50 28.00% 6/16 37.5% 0.68
26/55 47.23% 5/20 25.0% 0.14
20/51 39.22% 5/16 31.2% 0.78
4/20 20.00% 1/14 7.1% 0.379
4/13 30.77% 0/14 0.0% 0.041
9/46 19.57% 4/21 19.0% 0.676
11/32 34.38% 2/15 13.5% 0.175
46/65 70.7% 10/25 40.0% 0.014
ers (OC) are presented in this table.
zygosity.
Figure 1 An explanatory chart of LOH. Eight breast cancer tissues exhibited LOH at all of the informative loci tested at Xq25, and their XCI
patterns tended to be non-random. The figure demonstrates the results of LOH by microsatellite analysis at Xq25. The horizontal axis indicates
the position of the 11 microsatellite makers and the vertical axis indicates the case numbers of the 22 breast cancers. Legend: Red rectangles,
LOH was detected; open rectangles, retention of heterozygosity; blue rectangles, uninformative cases.
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normal tissues
The XCI pattern was defined as random or non-random, as
previously described [25]. Thirteen breast cancer patients’
XCI patterns were NN (non-random in tumour tissue/non-
random in adjacent normal tissue; 22.8%), 21 were NR
(non-random in tumour tissue/random in adjacent normal
tissue; 36.8%), and the other 23 were RR (random in
tumour tissue/random in adjacent normal tissue; 40.3%).
The XCI patterns in the tumour and adjacent normal tis-
sues of the 17 other non-breast cancer patients were 3 NN
(18%), 3 NR (18%), and 11 RR (65%; Figures 2 and 3).Figure 2 XCI Pattern in breast cancer tissues. XCI pattern in the
57 breast cancer patients’ tumour and adjacent normal tissues (RR,
NR or NN). Thirteen breast cancer patients’ XCI patterns were NN
(22.8%), 21 were NR (36.8%), and the other 23 were RR (40.3%).Relationships between microsatellite analysis, XCI pattern,
and clinical parameters
Eight of the 65 breast cancer samples (B44, B113, B130,
B129, B307, B320, B322, and B323) showed LOH at all of
the informative loci tested at Xq25. The XCI patterns of
B129 and B320 were NN, those of B113, B322, and B130
were NR, and B44 was RR. The patterns of XCI in B307 and
B323 were not able to be detected because of homozygosity.
Interestingly, the patterns of XCI in the tumour tissues of
these eight breast cancers tended to be non-random.
An analysis of the relationships between microsatellite
analysis, XCI pattern, and clinical symptoms (includingtumour grade, lymph node metastases, and tumour size)
is presented in Tables 2 and 3. A correlation analysis of
LOH pattern and tumour clinicopathological character-
istics revealed that LOH at Xq25 or DXS1047 was not
associated with higher histologic grade or axillary lymph
node metastasis (Table 3).
AR cytosine, adenine, guanine repeats
We estimated the frequencies of AR alleles to evaluate
the association between AR-CAG repeats and breast
cancer risk. The CAG repeats of the breast cancer sam-
ples were compared with those of similarly-aged healthy
Figure 3 XCI Pattern in non-breast cancer tissues. The XCI
pattern in the 17 other cancer patients’ tumour and adjacent normal
tissues (RR, NR or NN). Three other cancer patients’ XCI patterns
were NN (18%), 3 were NR (18%), and 11 were RR (65%).
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CAG repeats) were found to possess an increased risk of
breast cancer, while those with two short AR alleles (<21
CAG repeats) were likely to be normal (p = 0.00069; 95%
confidence interval 0.5 ~ −0.13). However, when compar-
ing breast cancer patients with young healthy controls,
no significant relationships were identified (Table 4).
Discussion
LOH at Xq25 was determined by examining the frequency
of heterozygosity 11 markers in normal tissue DNA and
in patients with breast cancer (Table 1). The frequency of
heterozygosity of these markers should be greater than
80%. However, some microsatellite markers had a low het-
erozygosity frequency (DXS8067, DXS8059, DXS8078,
DXS8071, and DXS8074), indicating that the allele distri-
bution varies amongst populations. Highly polymorphic
markers have a high frequency of heterozygosity which
is necessary for suitable analysis of LOH in tumour
DNA. The ultimate goal of this project was to identify aTable 2 Relationships between microsatellite analysis, XCI pa





Tumour Grade 1.2 15/19 78.9% Tu
Tumour Grade 3 4/19 21.1% Tu
LNMc+ 13/19 68.4%
LNMd– 6/19 31.6%
Tumour Size (<3 cm) 8/17 47.1% Tum
Tumour Size (>3 cm) 9/17 52.9% Tum
This table presents the relationships between microsatellite analysis, XCI pattern, an
tumour size).
a. N: The XCI pattern in the tumour tissues was non-random.
b. R: The XCI pattern in the tumour tissues was random.
c. LNM+: Patients with lymph node metastases.
d. LNM–: Patients without lymph node metastases.
e. Chi-square test and Fisher’s exact probability test.candidate TSG. Chromosome arm Xq25 is one of the
most frequent LOH regions observed in breast and ovar-
ian cancers [20]. Here LOH of at least one microsatellite
locus at Xq25 was identified in 70.7% (46/65) breast can-
cer patients, which is higher than the percentages reported
in previous studies. In comparison, LOH of at least one
locus on 7q31 was detected in 34% of sporadic prostate
tumours, and the candidate tumour suppressor gene TES
was found here [26]. LOH of at least one locus on 9q was
observed in 56% of transitional cell carcinomas (TCCs) in
bladder cancer [27], and LOH of at least one locus at
17q21 (BRCA1 locus) was found in 60.53% of breast can-
cers [28]. Candidate TSGs in these regions were subse-
quently identified. The high frequency of LOH at Xq25
identified in Taiwanese breast cancer patients here indicates
that one or more novel candidate TSGs exists at Xq25.
It is possible that one hit to a TSG localized on the X
chromosome could be sufficient to induce carcinogen-
esis because the other allele is inactivated, and several
lines of evidence support the hypothesis of the existence
of a tumour suppressor gene on Xq25. The X chromo-
some is involved in the establishment of in vitro immor-
tality and may therefore be important for the control of
cell proliferation [29]. In 2002, it was announced that a
candidate TSG on the X chromosome was identified
using chromosome transfer experiments [30]. Addition-
ally, deletions at Xq25 have been reported to be associ-
ated with ovarian cancer [20], and Piao et al. found a
high frequency of LOH on chromosome arm Xq in
breast cancer cells [31]. Piao et al. also identified that
LOH of DXS8098 at Xq25 is associated with a larger
tumour size (>3 cm), a higher histologic grade, and axil-
lary lymph node metastasis, suggesting that there could be
one or more TSGs in this region [21]. The frequency ofttern, and clinical parameters
Patients in which LOH was observed at one or
more microsatellite markers




mour Grade 1.2 30/44 68.18%
0.55




our Size (<3 cm) 22/45 48.89%
0.88
our Size (>3 cm) 23/45 51.11%
d clinical parameters (including tumour grade, lymph node metastases, and
Table 3 Relationships between microsatellite analysis (DXS1047), XCI pattern, and clinical parameters
Patients in whom no LOH was found at the DXS1047
microsatellite marker
Patients in whom LOH was found at the DXS1047
microsatellite marker
No. % No. % P valuee
Ra 14/24 58.3% Ra 10/20 50%
0.80
Nb 10/24 41.7% Nb 10/20 50%
Tumour Grade 1.2 22/28 78.6% Tumour Grade 1.2 15/25 60%
0.24
Tumour Grade 3 6/28 21.4% Tumour Grade 3 10/25 40%
LNMc+ 17/28 60.7% LNMc+ 12/28 42.9%
0.28
LNMd– 11/28 39.2% LNMd– 14/28 57.1%
Tumour Size (<3 cm) 11/28 39.3% Tumour Size (<3 cm) 14/26 53.8%
0.28
Tumour Size (>3 cm) 17/28 60.7% Tumour Size (>3 cm) 12/26 46.2%
This table presents the relationships between microsatellite analysis (DXS1047), XCI pattern, and clinical parameters (including tumour grade, lymph node
metastases, and tumour size).
a. N: The XCI pattern in the tumour tissues was non-random.
b. R: The XCI pattern in the tumour tissues was random.
c. LNM+: Patients with lymph node metastases.
d. LNM–: Patients without lymph node metastases.
e. Chi-square test and Fisher’s exact probability test.
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more common in breast cancers (70.7%) than in other
cancers (40%) in our study. These results demonstrate a
significant (p = 0.014) correlation between LOH at Xq25
and breast cancer risk. The DXS1047 marker showed the
highest LOH (47.23%) of the markers tested, and we hy-
pothesized that the regions adjacent to DXS1047 contain
one or more candidate TSGs with important roles in
breast carcinogenesis but not in other kind of cancers
(Table 1).
The XCI patterns in the 57 breast and other cancer tis-
sues were found to be of NN, NR or RR types (Figures 2
and 3). XCI patterns in the breast cancer tumour tissues
tended to be non-random, and differed from the other
kinds of cancer examined (p = 0.047). These results are
similar to those of previous studies, in which non-random
XCI patterns have been found to be a predisposing factor
for the development of invasive ovarian cancer [24].
If a TSG is localized on the X chromosome, a single
step, either a mutation or loss of the active allele from
the active X chromosome, is sufficient to induce
carcinogenesis because the other allele congenitally
inactivated. Large deletions at Xq25 were identified in
eight of the breast cancer samples with all of theTable 4 Androgen receptor cytosine, adenine, guanine
repeats
Breast cancer Old controlsa Young controlsb
(CAG) n, n ≥ 21 42 37 20
(CAG) n, n < 21 2 20 6
In this table, the women with longer CAG repeats (≥ 21) and those with
shorter CAG repeats (< 21) are evaluated separately.
a. Old controls: healthy controls of a similar age to the breast cancer patients.
b. Young controls: younger healthy controls.informative loci tested at Xq25 found to have LOH.
Additionally, the patterns of XCI of these eight breast can-
cer tumour tissues tended to be non-random, indicating
that the origin of these breast cancer tissues was monoclo-
nal. Thus, carcinogenesis in these patients could be par-
tially explained by two hits to a TSG at Xq25. Here, the
first hit is X chromosome condensation and the second is
the large deletion at Xq25, which presumably occurs on
the active chromosome. In summary, the fact that fre-
quent LOH at Xq25 of the X chromosome was observed
in breast cancer tissues suggests that the X chromosome
may indeed harbour one or more TSGs, which might play
an important role in breast cancer carcinogenesis.
In this study, an increasing number of CAG repeats
was found to be associated with elevated breast cancer
risk. Multiple studies have previously indicated associa-
tions between the length of the CAG repeat and the risk
of ovarian [14], breast [15,16] and endometrial cancers
[17,18], whereas some breast cancer studies have re-
ported no association [16,32].
We compared the CAG repeat length of the breast
cancer patients with those of similarly-aged healthy con-
trols, and found that two long AR alleles (≥21 CAG re-
peats) was associated with an increased risk of breast
cancer, while women with two short AR alleles (<21
CAG repeats) were likely to be normal (p = 0.00069).
However, when comparing the breast cancer patients
with the young healthy controls, no significant relation-
ship was observed (Table 4). This suggests that the
young healthy control individuals with longer AR alleles
might be at increased risk of developing breast cancer
later in life, though they are currently in good health.
These results further suggest that longer AR alleles may
contribute to carcinogenesis in women.
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This study identifies an extraordinary high frequency of
LOH at Xq25 in Taiwanese patients with breast cancer.
This strongly implies that there might be one or more
TSGs related to the development of breast cancer at Xq25
in this population.
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